CD274 and non-small cell lung carcinoma: (19) focused specifically on a subgroup of patients who received PD-1/PD-L1 inhibitors as treatment for NSCLC BM and found that specific clinical parameters, such as age <70 years, prior CNS radiation, and the synchronous appearance of BM, significantly affected ICB disease control.